Afriplex, in collaboration with the Cannabis Research Institute, is once again putting South African Cannabis industry on the map as it has developed technology to extract cannabidiol (CBD) isolate from locally cultivated cannabis. Unlike full-spectrum CBD products, CBD isolate does not contain tetrahydrocannabinol (THC), the psychoactive component of cannabis. With CBD isolate, consumers can relieve pain and inflammation, boost immune function, and reduce anxiety, just as they can with other CBD products.
Through conceptualisation, testing, and development, Afriplex produces novel and commercially viable products for local and international markets as part of the cannabis giant, ImpiloVest. It places a high degree of emphasis on the safety and efficacy of its products due to its status as one of Africa’s leading brands in the areas of botanical extracts, complementary medicines, food and beverage products, and food and beverage product development.
According to Arno Roux, the facility’s Managing Director, the CBD market will continue to grow in SA, and with technology like this, growth will be accelerated even more. By 2026, the local market is estimated to be worth R406.3 million. He says, “In partnership with the CRI, we have managed to extract and crystalise CBD from locally sourced material, making it suitable for those who do not desire the effects of THC. This latest offering will potentially pave the way for export opportunities to regions such as Europe, North America, and South America looking to source good quality supply.”